ICJIM
Intercontinental Journal of Internal Medicine

The Intercontinental Journal of Internal Medicine aims to publish issues related to all fields of internal medicine of the highest scientific and clinical value at an international level and accepts articles on these topics. This journal is indexed by indices that are considered international scientific journal indices (DRJI, ESJI, OAJI, etc.). According to the current Associate Professorship criteria, it is within the scope of International Article 1-d. Each article published in this journal corresponds to 5 points.

eISSN: 2980-0846
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
TSH receptor autoantibody levels in patients with non-toxic diffuse and nodular goiter
Abstract
Aims: To investigate TSH receptor antibody (TRAb) levels in patients with diffuse and nodular goiter and in patients which undergo thyroid operation.
Methods: 40 patients with non-toxic diffuse goiter (NTDG), 20 patients with non-toxic nodular goiter (NTNG), 20 patients undergo thyroid operation and 34 healthy subjects were involved. Thyroid function tests, TRAb levels were measured. All the patients were done thyroid sonography. In the opereation group, preoperative, postoperative 10th and 30th day TRAbs were studied.
Results: TRAb was significantly elevated in 20% of patients with NTNG, 30% of patients with NTDG and 35% of patients in the operation group (p>0.05). No TRAb(+) patient was found in the control group. TRAb levels in the postoperative period in the operated group were higher than in the preoperative period.
Conclusion: TRAb was found in euthyroid patients with goiter, different from the control group. In the group operated for goiter, postoperative TRAb levels were higher than preoperative levels. These findings indicated that autoimmunity may be involved in the development of non-toxic goiter.

Keywords : TSH receptor antibody, non-toxic, diffuse goiter, nodular goiter

Download Article


1. Maravall FJ, Gómez-Arnáiz N, Gumá A, et al. Reference values of thyroidvolume in a healthy, non-iodine-deficient Spanish population. HormMetab Res. 2004;36(9):645-649.
2. Teng W, Shan Z, Teng X, et al. Effect of iodine intake on thyroid diseasesin China.N Engl J Med.2006;354(26):2783-2793.
3. Knobel M. Etiopathology, clinical features, and treatment of diffuse andmultinodular nontoxic goiters.J Endocrinol Invest.2016;39(4):357-373.
4. Unlu MT, Kostek M, Aygun N, Isgor A, Uludag M. Non-toxicmultinodulargoiter: from etiopathogenesis to treatment. Sisli EtfalHastan Tip Bul. 2022;56(1):21-40.
5. Shimojo N, Kohno Y, Yamaguchi K, et al. Induction of Graves-likedisease in mice by immunization with fibroblasts transfected with thethyrotropin receptor and a class II molecule. Proc Natl Acad Sci USA.1996;93(20):11074-11049.
6. Chiovato L, Bassi P, Santini F, et al. Antibodies producing complement-mediated thyroid cytotoxicity in patients with atrophic or goitrousautoimmune thyroiditis. J Clin Endocrinol Metab. 1993;77(6):1700-1705.
7. Smith BR, Hall R. Thyroid-stimulating immunoglobulins in Graves’disease. Lancet. 1974;2(7878):427-431.
8. Morshed SA, Davies TF. Graves’ disease mechanisms: the roleofstimulating, blocking, and cleavage region TSH receptorantibodies.Horm Metab Res. 2015;47(10):727-734.
9. Davies TF, Latif R. Editorial: TSH Receptor and Autoimmunity. FrontEndocrinol (Lausanne). 2019;10:19.
10. Krohn K, Wohlgemuth S, Gerber H, Paschke R. Hot microscopic areas ofiodine deficient euthyroid goiters contain constitutively activating TSHreceptor mutations. J Pathol. 2000;192(1):37-42.
11. Vassart G. Activating mutations of the TSH receptor. Thyroid. 2004;14(1):86-87.
12. Krohn K,Fu¨hrer D,Bayer Y, et al. Molecular pathogenesis of euthyroidand toxic multinodular goiter.Endocr Rev. 2005;26(4):504-524.
13. Fenzi GF, Bartalena L, Lombardi A. Thyroid autoimmunity and endemicgoiter. Endocrinol Exp. 1986;20(1):49-56.
14. Rootwelt K. Evaluation of a radioreseptor assay for TSH receptorautoantibodies. Scand J Clin Lab Invest. 1988;48(2):157-164.
15. Berghout A, Wiersing WM, Smits NJ. Determinants of thryoid volu¨me asmeasured by ultrasonography in healthy adults in a non-iodine deficientarea. Clin Endocrinology. 1987;26(3):273-280.
16. Vargas-Uricoechea H. Molecular mechanisms in autoimmune thyroiddisease. Cells. 2023;12(6):918.
17. Zonenberg A, Kinalska I, Zarzycki W. Incidence of thryoid autoantibodiesin the endemic goiter. Horm Metab Res. 1994;(26):238-242.
18. Zimmermann MB, Boelaert K. Iodine deficiency and thyroid disorders.Lancet Diabetes Endocrinol. 2015;3(4):286-295.
19. Yildirim Simsir I, Cetinkalp S, Kabalak T. review of factors contributingto nodulargoiterand thyroid carcinoma. Med Princ Pract. 2020;29(1):1-5.
20. Huo Y, Xie J, Chen S, Wang H, Ma C. Recombinant human thyrotropin(rhTSH)-aided radioiodine treatment for non-toxic multinodular goitre.Cochrane Database Syst Rev. 2021;12(12):CD010622.
21. Vargas-Uricoechea H, Nogueira JP, Pinzón-Fernández MV, SchwarzsteinD. The usefulness of thyroid antibodies in the diagnostic approach toautoimmune thyroid disease. Antibodies (Basel). 2023;12(3):48.
22. Morshed SA,Davies TF. Graves’ disease mechanisms: the role ofstimulating, blocking, and cleavage region TSH receptor antibodies.Horm Metab Res.2015;47(10):727-734.
23. Furmaniak J,Sanders J,Sanders P,Miller-Gallacher J,Ryder MM,ReesSmith B. Practical applications of studies on the TSH receptor and TSHreceptor autoantibodies. Endocrine. 2020;68(2):261-264.
24. Diana T,Krause J,Olivo PD,et al. Prevalence and clinical relevanceof thyroid stimulating hormone receptor-blocking antibodies inautoimmune thyroid disease. Clin Exp Immunol.2017;189(3):304-309.
25. Hegedu¨s L, Bonnema SJ, Bennedbaek FN. Management of simplenodular goiter: current status and future perspectives. Endocr Rev. 2003;24(1):102-132.
26. Baloch ZW, LiVolsi VA. Current role and value of fine-needle aspirationin nodular goitre.Best Pract Res Clin Endocrinol Metab.2014;28(4):531-544.
27. Smith PP, McMullan NM, Grubeck-Loebenstein B. Thyroid growth-stimulating immunoglobulins in goitrous disease. Relationship tothyroid-stimulating immunoglobulins. Acta Endocrinol. 1986;111(3):321-330.
28. Nygaard B, Knudsen JH, Hegedu¨s L, Scient AV, Hansen JE. Thyrotropinreceptor antibodies and Graves’ disease, a side-effect of 131I treatment inpatients with nontoxic goiter.J Clin Endocrinol Metab.1997;82(9):2926-2930.
29. Sugenoya A, Kobayashi S, Kasuga Y, et al. Evidence of intrathyroidalaccumulation of TSH receptor antibody in Graves’ disease. ActaEndocrinol (Copenh). 1992;126(5):416-418. doi:10.1530/acta.0.1260416
30. Lee JK, Kong Y, Choi JB, et al. TSH receptor antibody as a predictor ofdifficult robotic thyroidectomy in patients with Graves’ disease. J RobotSurg. 2024;18(1):108. doi:10.1007/s11701-024-01869-y
31. Iwanaga H, Fujita N, Abe S, Naganawa S, Kato K. Correlation betweenthe thyroid computed tomography value and thyroid function inhyperthyroidism: a retrospective study. Ann Nucl Med. 2024;38(8):659-665. doi:10.1007/s12149-024-01938-0
Article available in :
Volume 2, Issue 4, 2024
Page : 77-81
https://doi.org/10.51271/ICJIM-0041
Article Information
Received : 08 Eki 2024
Accepted : 20 Eki 2024
Published : 30 Eki 2024
Corresponding Author :

Zeynep Çetin: Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Amasya University, Amasya, Turkiye

[email protected]
Citation : Dortok Demir H, Çetin Z, Çelik C. TSH receptor autoantibody levels in patients with non-toxic diffuse and nodular goiter. Intercont J Int Med. 2024;2(4):77-81.

Read: 79
Cited: 0
Download : 31
_Footer